ClinicaliQ Trial Snapshot
- A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE) — Recruiting • Phase III • NCT06858579.
- A new drug (claseprubart) tested against placebo in adults with chronic inflammatory demyelinating polyneuropathy to assess whether it works and is safe.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this Phase 3 study is to demonstrate the efficacy of claseprubart (DNTH103) as compared to placebo in participants with chronic inflammatory demyelinating polyneuropathy (CIDP). Conditions: Chronic Inflammatory Demyelinating Polyneuropathy Interventions: Claseprubart, Claseprubart, Placebo Lead Sponsor: Dianthus Therapeutics Planned Enrollment: 256 participants